SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION

George P. Canellos, James C. Arseneau, Vincent T. Devita, Jacqueline Whang-Peng, Ralph E.C. Johnson

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

The incidence of second tumours Summary occurring in the course of Hodgkin's disease has been investigated in a series of 452 patients treated with standard chemotherapy or radiotherapy, combination chemotherapy alone, intensive radiotherapy alone, or both intensive radiotherapy and combination chemotherapy administered in sequence. 16 tumours were noted. When analysed according to mode of treatment, 6 cases occurred in a group of 62 patients who received both modalities. When analysed for age, sex, and man-years of follow-up, this group appears to have 14·5 times the risk of developing a second tumour. However, that subgroup which had a complete remission after intensive radiotherapy followed by a relapse of disease, prior to receiving combination chemotherapy, had the highest risk with 18·5 times greater incidence of second tumour than expected. It is noteworthy that, of the 16 second tumours, 2 were acute myeloid leukæmia; in both cases a similar chromosomal abnormality (45 chromosomes, C-group deletion) was noted. The mechanism of oncogenesis may represent a combination of the immunosuppressive effects and cellular effects of those forms of treatment.

Original languageEnglish
Pages (from-to)947-949
Number of pages3
JournalThe Lancet
Volume305
Issue number7913
DOIs
Publication statusPublished - Apr 26 1975
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Hodgkin Disease
Radiotherapy
Combination Drug Therapy
Neoplasms
Chromosomes, Human, 6-12 and X
Incidence
Immunosuppressive Agents
Chromosome Aberrations
Carcinogenesis
Recurrence
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Canellos, G. P., Arseneau, J. C., Devita, V. T., Whang-Peng, J., & Johnson, R. E. C. (1975). SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION. The Lancet, 305(7913), 947-949. https://doi.org/10.1016/S0140-6736(75)92007-3

SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION. / Canellos, George P.; Arseneau, James C.; Devita, Vincent T.; Whang-Peng, Jacqueline; Johnson, Ralph E.C.

In: The Lancet, Vol. 305, No. 7913, 26.04.1975, p. 947-949.

Research output: Contribution to journalArticle

Canellos, GP, Arseneau, JC, Devita, VT, Whang-Peng, J & Johnson, REC 1975, 'SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION', The Lancet, vol. 305, no. 7913, pp. 947-949. https://doi.org/10.1016/S0140-6736(75)92007-3
Canellos, George P. ; Arseneau, James C. ; Devita, Vincent T. ; Whang-Peng, Jacqueline ; Johnson, Ralph E.C. / SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION. In: The Lancet. 1975 ; Vol. 305, No. 7913. pp. 947-949.
@article{8553baa86fd04d8fbbd668df6220fdf9,
title = "SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION",
abstract = "The incidence of second tumours Summary occurring in the course of Hodgkin's disease has been investigated in a series of 452 patients treated with standard chemotherapy or radiotherapy, combination chemotherapy alone, intensive radiotherapy alone, or both intensive radiotherapy and combination chemotherapy administered in sequence. 16 tumours were noted. When analysed according to mode of treatment, 6 cases occurred in a group of 62 patients who received both modalities. When analysed for age, sex, and man-years of follow-up, this group appears to have 14·5 times the risk of developing a second tumour. However, that subgroup which had a complete remission after intensive radiotherapy followed by a relapse of disease, prior to receiving combination chemotherapy, had the highest risk with 18·5 times greater incidence of second tumour than expected. It is noteworthy that, of the 16 second tumours, 2 were acute myeloid leuk{\ae}mia; in both cases a similar chromosomal abnormality (45 chromosomes, C-group deletion) was noted. The mechanism of oncogenesis may represent a combination of the immunosuppressive effects and cellular effects of those forms of treatment.",
author = "Canellos, {George P.} and Arseneau, {James C.} and Devita, {Vincent T.} and Jacqueline Whang-Peng and Johnson, {Ralph E.C.}",
year = "1975",
month = "4",
day = "26",
doi = "10.1016/S0140-6736(75)92007-3",
language = "English",
volume = "305",
pages = "947--949",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7913",

}

TY - JOUR

T1 - SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION

AU - Canellos, George P.

AU - Arseneau, James C.

AU - Devita, Vincent T.

AU - Whang-Peng, Jacqueline

AU - Johnson, Ralph E.C.

PY - 1975/4/26

Y1 - 1975/4/26

N2 - The incidence of second tumours Summary occurring in the course of Hodgkin's disease has been investigated in a series of 452 patients treated with standard chemotherapy or radiotherapy, combination chemotherapy alone, intensive radiotherapy alone, or both intensive radiotherapy and combination chemotherapy administered in sequence. 16 tumours were noted. When analysed according to mode of treatment, 6 cases occurred in a group of 62 patients who received both modalities. When analysed for age, sex, and man-years of follow-up, this group appears to have 14·5 times the risk of developing a second tumour. However, that subgroup which had a complete remission after intensive radiotherapy followed by a relapse of disease, prior to receiving combination chemotherapy, had the highest risk with 18·5 times greater incidence of second tumour than expected. It is noteworthy that, of the 16 second tumours, 2 were acute myeloid leukæmia; in both cases a similar chromosomal abnormality (45 chromosomes, C-group deletion) was noted. The mechanism of oncogenesis may represent a combination of the immunosuppressive effects and cellular effects of those forms of treatment.

AB - The incidence of second tumours Summary occurring in the course of Hodgkin's disease has been investigated in a series of 452 patients treated with standard chemotherapy or radiotherapy, combination chemotherapy alone, intensive radiotherapy alone, or both intensive radiotherapy and combination chemotherapy administered in sequence. 16 tumours were noted. When analysed according to mode of treatment, 6 cases occurred in a group of 62 patients who received both modalities. When analysed for age, sex, and man-years of follow-up, this group appears to have 14·5 times the risk of developing a second tumour. However, that subgroup which had a complete remission after intensive radiotherapy followed by a relapse of disease, prior to receiving combination chemotherapy, had the highest risk with 18·5 times greater incidence of second tumour than expected. It is noteworthy that, of the 16 second tumours, 2 were acute myeloid leukæmia; in both cases a similar chromosomal abnormality (45 chromosomes, C-group deletion) was noted. The mechanism of oncogenesis may represent a combination of the immunosuppressive effects and cellular effects of those forms of treatment.

UR - http://www.scopus.com/inward/record.url?scp=84920206761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920206761&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(75)92007-3

DO - 10.1016/S0140-6736(75)92007-3

M3 - Article

VL - 305

SP - 947

EP - 949

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7913

ER -